Stock 1875 TOT BIOPHARM INTERNATIONAL COMPANY LIMITED
Add to a list
To use this feature you must be a member
Log inSign up

TOT BIOPHARM International Company Limited Share Price

Equities

1875

HK0000545266

Biotechnology & Medical Research

Market Closed - Hong Kong S.E.
Other stock markets
 09:08:20 26/04/2024 BST 		5-day change 1st Jan Change
1.68 HKD +6.33% Intraday chart for TOT BIOPHARM International Company Limited +8.39% -14.72%
03-15 TOT BIOPHARM International Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
2023 TOT Biopharm's Loss Narrows in January-September Period MT

Financials

Sales 2021 76.32M 10.53M 82.46M 844M Sales 2022 442M 61.02M 478M 4.89B Capitalization 1.64B 226M 1.77B 18.1B
Net income 2021 -261M -36.02M -282M -2.88B Net income 2022 -49M -6.76M -52.94M -542M EV / Sales 2021 28.7 x
Net Debt 2021 53.18M 7.34M 57.46M 588M Net cash position 2022 172M 23.7M 185M 1.9B EV / Sales 2022 3.32 x
P/E ratio 2021
-7.64 x
P/E ratio 2022
-27.1 x
Employees 552
Yield 2021 *
-
Yield 2022
-
Free-Float 58.01%
More Fundamentals * Assessed data

Chart TOT BIOPHARM International Company Limited

Dynamic Chart

Latest news about TOT BIOPHARM International Company Limited

TOT BIOPHARM International Company Limited Reports Earnings Results for the Full Year Ended December 31, 2023 CI
TOT Biopharm's Loss Narrows in January-September Period MT
TOT Biopharm's Loss Narrows in H1 MT
TOT BIOPHARM International Company Limited Announces Directorate and Committee Changes CI
TOT BIOPHARM International Company Limited Reports Earnings Results for the Half Year Ended June 30, 2023 CI
TOT BIOPHARM's Q1 Loss Widens Despite Higher Revenue MT
TOT BIOPHARM International Company Limited Reports Earnings Results for the Full Year Ended December 31, 2022 CI
TOT Biopharm Terminates Phase 3 Trial of Breast Cancer Drug; Shares Fall 5% MT
TOT BIOPHARM International Company Limited Announces Termination of Phase III Clinical Trial Study and Development of Taa013 CI
TOT BIOPHARM’s Production Base for Antibody Drug Receives Good Manufacturing Report from Europe MT
TOT BIOPHARM International Company Limited Announces Change of Address of Registered Office CI
TOT Biopharm International Logs Reduction in H1 Net Loss; Shares Climb 3% MT
TOT BIOPHARM International Company Limited Reports Earnings Results for the Half Year Ended June 30, 2022 CI
TOT BIOPHARM International Company Limited announced that it expects to receive HKD 110 million in funding from Center Laboratories, Inc. CI
TOT Biopharm Narrows Loss on Lower Selling, R&D Expenses in 2021 MT
More news

Press releases TOT BIOPHARM International Company Limited

Connected Transactions Involving Subscription by Vivo Suzhou Fund and Centerlab for TOP BIOPHARM Shares AQ
TOT BIOPHARM Announces NMPA Granted Marketing Approval for Pusintin® (TAB008, Bevacizumab Injection) in China PR
TOT BIOPHARM International : 2021 Interim Revenue Surges 78% to RMB23.13 million AQ
TOT BIOPHARM International : VOLUNTARY ANNOUNCEMENT - MARKETING APPROVAL FOR MEGESTROL ACETATE ORAL SUSPENSION (TOM218) OBTAINED FROM THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION PU
TOT BIOPHARM International : CERTAIN UNAUDITED FINANCIAL INFORMATION FOR THE THREE MONTHS ENDED 31 MARCH 2021 PU
More press releases

Quotes and Performance

1 day+6.33%
1 week+8.39%
Current month+1.82%
1 month+6.33%
3 months+4.35%
6 months-10.64%
Current year-14.72%
More quotes

Highs and lows

1 week
1.48
Extreme 1.48
1.68
1 month
1.48
Extreme 1.48
1.73
Current year
1.48
Extreme 1.48
2.02
1 year
0.80
Extreme 0.8
3.40
3 years
0.80
Extreme 0.8
5.00
5 years
0.80
Extreme 0.8
6.43
10 years
0.80
Extreme 0.8
6.43
More quotes

Managers and Directors - TOT BIOPHARM International Company Limited

Managers TitleAgeSince
Jun Liu CEO
 Chief Executive Officer 56 16/10/16
Ben Xiao DFI
 Director of Finance/CFO 42 31/12/21
Ming Liu CTO
 Chief Tech/Sci/R&D Officer 63 27/08/17
Members of the board TitleAgeSince
Chun-Ying Yeh-Huang BRD
 Director/Board Member 65 04/07/10
Hong Jen Chang BRD
 Director/Board Member 68 11/03/19
Shan Fu CHM
 Chairman 56 18/01/16
More insiders

Quotes

Date Price Change Volume
26/04/24 1.68 +6.33% 32,800
25/04/24 1.58 +4.64% 20,400
24/04/24 1.51 -3.82% 94,800
23/04/24 1.57 +1.95% 9,200
22/04/24 1.54 -0.65% 14,000

Delayed Quote Hong Kong S.E., April 26, 2024 at 09:08 am

More quotes

Company Profile

TOT BIOPHARM International Company Limited is a company mainly engaged in the development and commercialization of oncology drugs and therapies. The Company has a portfolio of oncology drug candidates, which include monoclonal antibodies (mAbs), antibody drug conjugates (ADCs), oncolytic virus products and specialty oncology drugs such as liposome drugs.
Sector
Biotechnology & Medical Research
Calendar
08/08/2024 - Q2 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
1.555 CNY
Average target price
3.486 CNY
Spread / Average Target
+124.16%
Consensus

Annual profits - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
TOT BIOPHARM INTERNATIONAL COMPANY LIMITED Stock TOT BIOPHARM International Company Limited
-14.72% 166M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-2.31% 103B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+0.56% 95.28B
ARGENX SE Stock argenx SE
+1.69% 22.15B
BIONTECH SE Stock BioNTech SE
-17.37% 21.02B
GENMAB A/S Stock Genmab A/S
-9.30% 18.15B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-41.01% 16.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-14.85% 16.05B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+3.21% 13.68B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+33.54% 12.17B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. 1875 Stock